Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
United Press International - October 13, 2007
The New Jersey company said Isentress is the first medicine to be approved in a new class of anti-retroviral drugs called integrase inhibitors. The drug works by inhibiting the insertion of HIV DNA into human DNA by the integrase enzyme, limiting the ability of the virus to replicate and infect new cells, Merck said Friday in a release.
The FDA said the drug can be used in combination with other anti-retroviral agents for the treatment of HIV-1 infection in adult patients who are resistant to other anti-retroviral agents.
071013
UPI071009
Copyright © 2007 - United Press International. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through United Press International, Permissions Desk, 1510 H St. N.W. Washington DC 2005. Main Phone Switchboard: 202-898-8000 FAX: 202-898-8057 or 202-898-8147 Email: info@upi.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .